Figure 3.
Risk of stage 2 or 3 acute kidney injury (AKI) between piperacillin-tazobactam (PTZ)/vancomycin (VAN) and other antibiotic combinations. No differences were observed between groups in unadjusted analyses or analyses adjusted for baseline AKI risk score. Reference antibiotic groups for the models were cefepime (CEF)/VAN and meropenem (MER)/VAN, respectively. Abbreviations: CI, confidence interval; OR, odds ratio.